Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that Seth Yon, Sanara’s President and Chief ...

FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that management will present at the Cantor Global Healthcare Conference, which is being held at the New York Marriott Marquis in New York, NY from Sept ...

Core Viewpoint - Sanara MedTech Inc. is set to report its second quarter 2025 financial results on August 13, 2025, focusing on transformative technologies in the medical field to enhance clinical outcomes and reduce healthcare costs [1][4]. Financial Results Announcement - The financial results for the quarter ending June 30, 2025, will be discussed in a conference call and webcast scheduled for August 13, 2025, at 8:00 a.m. Eastern Time [2]. - A toll-free number for the teleconference is provided, along with details for international callers and a replay option available until August 27, 2025 [2]. Company Overview - Sanara MedTech Inc. specializes in developing and commercializing technologies aimed at improving clinical outcomes in surgical, chronic wound, and skin markets [4]. - The company markets a range of products including CellerateRX Surgical Activated Collagen and FORTIFY TRG Tissue Repair Graft, primarily in the North American advanced wound care and surgical tissue repair markets [4]. - Sanara's product pipeline includes innovative candidates targeting opportunistic pathogens, wound healing, and tissue debridement, with a commitment to meeting quality and regulatory standards [4].

Core Insights - Sanara MedTech Inc. has launched a pilot program through its subsidiary Tissue Health Plus (THP) aimed at providing value-based wound care solutions for chronic wounds across six states [1][2] - The THP technology platform will serve as a Wound Care Operating System for a provider group, utilizing Co-Pilot software to standardize patient care and streamline administrative processes [2] - The pilot program is expected to validate and optimize the THP technology platform through real-world patient encounters, with plans for expansion to additional practitioners and locations [2] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies to improve clinical outcomes and reduce healthcare costs in surgical and chronic wound markets [4] - The company markets a range of surgical and wound care products primarily in the North American market, including CellerateRX Surgical Activated Collagen and various antimicrobial solutions [4][5] - THP aims to transform the $100+ billion wound care market by addressing gaps in chronic wound care, with a goal of improving healing rates to over 85% and reducing total care costs by more than 25% [3] Technology and Innovation - THP's platform combines AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized wound care [3] - The pilot program is part of a broader strategy to engage with payers and financial partners to support the implementation of THP's value-based care solutions [2][3]

Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary Ad ...

FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open. The Company will host a conference call a ...